Cognition Therapeutics
CGTX
46 hedge funds and large institutions have $8.82M invested in Cognition Therapeutics in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
2% less funds holding
Funds holding: 47 → 46 (-1)
4.93% less ownership
Funds ownership: 18.18% → 13.26% (-4.9%)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
32% less capital invested
Capital invested by funds: $12.9M → $8.82M (-$4.09M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$450K |
| 2 |
BlackRock
New York
|
+$193K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$119K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$59.8K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$53.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$3.18M |
| 2 |
CCM
Corsair Capital Management
New York
|
-$414K |
| 3 |
HWM
Hohimer Wealth Management
Seattle,
Washington
|
-$410K |
| 4 |
TIM
Timelo Investment Management
Aurora,
Ontario, Canada
|
-$238K |
| 5 |
CC
Carlson Capital
Dallas,
Texas
|
-$148K |
CGTX Hedge Fund Activity: Q2 2024 in Review
46 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q2 2024, worth a combined $8.82M — down 32% from $12.9M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CGTX and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 14 added.
The largest buyer was Vanguard Group, adding an estimated $450K. The largest seller was AIGH Capital Management, cutting an estimated $3.18M.
- 46 institutional investors held Cognition Therapeutics (CGTX) as of Q2 2024, down from 47 in Q1 2024.
- Funds reported $8.82M of Cognition Therapeutics stock for Q2 2024, down 32% quarter-over-quarter.
- 5 funds opened new Cognition Therapeutics positions in Q2 2024 and 6 closed out, a net change of -1 holder.
- The largest Cognition Therapeutics buyer in Q2 2024 was Vanguard Group, an estimated $450K added.
- The largest Cognition Therapeutics seller in Q2 2024 was AIGH Capital Management, an estimated $3.18M sold.
Based on aggregated 13F filings for Q2 2024.